FDA supplemental approval: Oxycodone AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental REMS submission for oxycodone-acetaminophen tablets in three dosage strengths (5/325 mg, 7.5/325 mg, and 10/325 mg) on 18 June 2026. This is a regulatory approval of risk management measures, not a clinical efficacy or safety trial, and does not contain trial outcomes or comparative data.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing oxycodone-acetaminophen combination, representing a regulatory action rather than new clinical evidence of efficacy or safety.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action represents approval of risk management procedures for an existing combination analgesic. Clinicians should consult the approved REMS terms to understand any new prescribing, dispensing, or monitoring requirements; this action does not itself provide evidence of clinical efficacy, safety, or comparative benefit.

Caveats

• This is a regulatory action record and does not contain clinical trial results, efficacy data, or safety trial outcomes.
• The submission type 'REMS' indicates risk mitigation measures; the specific content of the approved REMS plan is not detailed in this record.
• No information on the clinical rationale, post-marketing surveillance requirements, or changes to product labeling is provided.
• This record does not support judgements about clinical effectiveness or comparative advantage over other analgesics.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.